文献速递妇科肿瘤

脆弱老年卵巢癌患者一线单药卡铂对比卡铂联合紫杉醇的疗效与安全性

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项国际多中心三臂随机试验纳入120例Geriatric Vulnerability Score≥3的70岁以上晚期卵巢癌患者,比较每3周卡铂-紫杉醇、单药卡铂和每周卡铂-紫杉醇方案。因单药卡铂生存结局显著更差,试验被独立数据监查委员会提前终止;标准每3周联合方案完成6周期比例65%,治疗相关不良事件发生率43%。

要点

  • 脆弱老年卵巢癌患者中,单药卡铂较含紫杉醇联合方案生存显著更差。
  • 标准每3周卡铂-紫杉醇完成6周期比例65%,治疗相关不良事件发生率43%。
  • 单药卡铂和每周联合方案治疗相关不良事件发生率均为58%。

核心结论

  • 在脆弱老年晚期卵巢癌患者中,单药卡铂较每3周或每周卡铂-紫杉醇方案活性更低且生存结局显著更差。

研究设计与样本

  • 国际开放标签三臂随机临床试验,筛查447例70岁以上新诊断III/IV期卵巢癌女性,纳入120例Geriatric Vulnerability Score≥3患者并按国家和手术结局分层。
  • 研究在法国、意大利、芬兰、丹麦、瑞典和加拿大48个学术中心开展,入组时间为2013年12月11日至2017年4月26日。
  • 患者随机接受6周期每3周卡铂(AUC 5)+紫杉醇(175 mg/m2)、单药卡铂(AUC 5或6)每3周、或每周卡铂(AUC 2)+紫杉醇(60 mg/m2)第1、8、15天每4周方案。

主要发现

  • 独立数据监查委员会第三次会议建议终止试验,因单药卡铂与显著更差的生存相关。
  • 每3周联合组、单药卡铂组和每周联合组分别有26/40(65%)、19/40(48%)和24/40(60%)患者完成6周期治疗。
  • 治疗相关不良事件在标准每3周联合组为17/40(43%),低于单药卡铂组和每周联合组(均为23/40[58%])。
  • 治疗相关死亡共4例,每个联合组各2/40(5%)。

关键数值与推荐

  • 主要终点为治疗可行性,定义为完成6周期化疗且无疾病进展、因毒性提前终止治疗或死亡。
  • 入组标准为70岁及以上、新诊断III/IV期卵巢癌且Geriatric Vulnerability Score≥3。
  • 120例患者中位年龄80岁(四分位距76-83;范围70-94),43例(36%)GVS为4分,13例(11%)GVS为5分,40例(33%)为IV期。

临床怎么用

  • 对GVS≥3的脆弱老年晚期卵巢癌患者,不应以单药卡铂替代含紫杉醇的联合方案。
  • 每3周卡铂-紫杉醇联合方案在该人群中治疗相关不良事件发生率低于单药卡铂和每周联合方案。

局限性

  • 试验因单药卡铂生存显著更差而提前终止,样本量仅120例。
  • 开放标签设计可能影响不良事件评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Single-agent carboplatin is often proposed instead of a conventional carboplatin-paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an approach could have a detrimental effect on outcomes for these patients. OBJECTIVE: To compare the feasibility, efficacy, and safety of single-agent carboplatin every 3 weeks, weekly carboplatin-paclitaxel, or conventional every-3-weeks carboplatin-paclitaxel in vulnerable older patients with ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS: This international, open-label, 3-arm randomized clinical trial screened 447 women 70 years and older with newly diagnosed stage III/IV ovarian cancer by determining their Geriatric Vulnerability Score; 120 patients with a Geriatric Vulnerability Score of 3 or higher were stratified by country and surgical outcome. Enrollment took place at 48 academic centers in France, Italy, Finland, Denmark, Sweden, and Canada from December 11, 2013, to April 26, 2017. Final analysis database lock April 2019. Data analysis was performed from February 1 to December 31, 2019. INTERVENTIONS: Patients were randomized to receive 6 cycles of (1) carboplatin, area under the curve (AUC) 5 mg/mL·min, plus paclitaxel, 175 mg/m2, every 3 weeks; (2) single-agent carboplatin, AUC 5 mg/mL·min or AUC 6 mg/mL·min, every 3 weeks; or (3) weekly carboplatin, AUC 2 mg/mL·min, plus paclitaxel, 60 mg/m2, on days 1, 8, and 15 every 4 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was treatment feasibility, defined as the ability to complete 6 chemotherapy cycles without disease progression, premature toxic effects-related treatment discontinuation, or death. RESULTS: A total of 120 women were randomized. The mean and median age was 80 (interquartile range, 76-83; range, 70-94) years; 43 (36%) had a Geriatric Vulnerability Score of 4 and 13 (11%) had a Geriatric Vulnerability Score of 5; 40 (33%) had stage IV disease. During its third meeting, the independent data monitoring committee's recommendation led to the termination of the trial because single-agent carboplatin was associated with significantly worse survival. Six cycles were completed in 26 of 40 (65%), 19 of 40 (48%), and 24 of 40 (60%) patients in the every-3-weeks combination, single-agent carboplatin, and weekly combination groups, respectively. Treatment-related adverse events were less common with the standard every-3-weeks combination (17 of 40 [43%]) than single-agent carboplatin or weekly combination therapy (both 23 of 40 [58%]). Treatment-related deaths occurred in 4 patients (2 of 40 [5%] in each combination group). CONCLUSIONS AND RELEVANCE: This randomized clinical trial shows that compared with every-3-weeks or weekly carboplatin-paclitaxel regimens, single-agent carboplatin was less active with significantly worse survival outcomes in vulnerable older patients with ovarian cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02001272.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Falandry C, Rousseau F, Mouret-Reynier MA, et al. Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33885718. doi:10.1001/jamaoncol.2021.0696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。